Literature DB >> 22905960

Epigenetic drugs for Alzheimer's disease: hopes and challenges.

Filippo Caraci, Gian Marco Leggio, Filippo Drago, Salvatore Salomone.   

Abstract

Entities:  

Mesh：

Year:  2013        PMID： 22905960      PMCID： PMC3612736          DOI： 10.1111/j.1365-2125.2012.04443.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN： 0306-5251            Impact factor:   4.335


× No keyword cloud information.
  14 in total

1.  Chronic mild stress accelerates the onset and progression of the Alzheimer's disease phenotype in Tg2576 mice.

Authors:  Mar Cuadrado-Tejedor; Ana Ricobaraza; Diana Frechilla; Rafael Franco; Alberto Pérez-Mediavilla; Ana Garcia-Osta
Journal:  J Alzheimers Dis       Date:  2012       Impact factor: 4.472

2.  Histone deacetylase inhibitors impair NK cell viability and effector functions through inhibition of activation and receptor expression.

Authors:  Lucas E Rossi; Damián E Avila; Raúl G Spallanzani; Andrea Ziblat; Mercedes B Fuertes; Lara Lapyckyj; Diego O Croci; Gabriel A Rabinovich; Carolina I Domaica; Norberto W Zwirner
Journal:  J Leukoc Biol       Date:  2011-11-28       Impact factor: 4.962

Review 3.  Epigenetic protein families: a new frontier for drug discovery.

Authors:  Cheryl H Arrowsmith; Chas Bountra; Paul V Fish; Kevin Lee; Matthieu Schapira
Journal:  Nat Rev Drug Discov       Date:  2012-04-13       Impact factor: 84.694

4.  The histone deacetylase inhibitor, romidepsin, suppresses cellular immune functions of cutaneous T-cell lymphoma patients.

Authors:  Michael J Kelly-Sell; Youn H Kim; Suzanne Straus; Bernice Benoit; Cameron Harrison; Katherine Sutherland; Randall Armstrong; Wen-Kai Weng; Louise C Showe; Maria Wysocka; Alain H Rook
Journal:  Am J Hematol       Date:  2012-02-24       Impact factor: 10.047

5.  Epigenetic drugs for Alzheimer's disease.

Authors:  Jacob Peedicayil
Journal:  Br J Clin Pharmacol       Date:  2013-04       Impact factor: 4.335

Review 6.  New pharmacological strategies for treatment of Alzheimer's disease: focus on disease modifying drugs.

Authors:  Salvatore Salomone; Filippo Caraci; Gian Marco Leggio; Julia Fedotova; Filippo Drago
Journal:  Br J Clin Pharmacol       Date:  2012-04       Impact factor: 4.335

Review 7.  Targeting the correct HDAC(s) to treat cognitive disorders.

Authors:  André Fischer; Farahnaz Sananbenesi; Alison Mungenast; Li-Huei Tsai
Journal:  Trends Pharmacol Sci       Date:  2010-10-25       Impact factor: 14.819

Review 8.  Adverse stress, hippocampal networks, and Alzheimer's disease.

Authors:  Sarah M Rothman; Mark P Mattson
Journal:  Neuromolecular Med       Date:  2009-11-27       Impact factor: 3.843

9.  HDAC2 negatively regulates memory formation and synaptic plasticity.

Authors:  Ji-Song Guan; Stephen J Haggarty; Emanuela Giacometti; Jan-Hermen Dannenberg; Nadine Joseph; Jun Gao; Thomas J F Nieland; Ying Zhou; Xinyu Wang; Ralph Mazitschek; James E Bradner; Ronald A DePinho; Rudolf Jaenisch; Li-Huei Tsai
Journal:  Nature       Date:  2009-05-07       Impact factor: 49.962

10.  An epigenetic blockade of cognitive functions in the neurodegenerating brain.

Authors:  Johannes Gräff; Damien Rei; Ji-Song Guan; Wen-Yuan Wang; Jinsoo Seo; Krista M Hennig; Thomas J F Nieland; Daniel M Fass; Patricia F Kao; Martin Kahn; Susan C Su; Alireza Samiei; Nadine Joseph; Stephen J Haggarty; Ivana Delalle; Li-Huei Tsai
Journal:  Nature       Date:  2012-02-29       Impact factor: 49.962
View more
  3 in total

1.  Novel Sustainable-by-Design HDAC Inhibitors for the Treatment of Alzheimer's Disease.

Authors:  Luiz Antonio Soares Romeiro; Jéssica Larissa da Costa Nunes; Camila de Oliveira Miranda; Gabriella Simões Heyn Roth Cardoso; Andressa Souza de Oliveira; Annachiara Gandini; Tereza Kobrlova; Ondrej Soukup; Michele Rossi; Johanna Senger; Manfred Jung; Silvia Gervasoni; Giulio Vistoli; Sabrina Petralla; Francesca Massenzio; Barbara Monti; Maria Laura Bolognesi
Journal:  ACS Med Chem Lett       Date:  2019-03-29       Impact factor: 4.345

Review 2.  Epigenetics: a novel therapeutic approach for the treatment of Alzheimer's disease.

Authors:  Lina Adwan; Nasser H Zawia
Journal:  Pharmacol Ther       Date:  2013-04-03       Impact factor: 12.310

3.  Epigenetic modifications of chronic hypoxia-mediated neurodegeneration in Alzheimer's disease.

Authors:  Hui Liu; Weidong Le
Journal:  Transl Neurodegener       Date:  2014-03-20       Impact factor: 8.014
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.